Moderna adds COO role. Moderna stock falls 1.40 percent

Published on 10/01/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 145.0 million and GAAP EPS was negative USD 1.97. Moderna stock costs EUR 166.54, down 1.40 percent from EUR 168.91.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna stock (ISIN US60770K1079) was trading at EUR 166.54 at Lang & Schwarz on October 1, 2026 at 10:03 a.m. CEST, down 1.40 percent versus the prior close of EUR 168.91. On September 30, Moderna added a chief operating officer role as it prepares for potential oncology launches, according to Moderna.

New COO role supports oncology plans

Juan Andres is set to return as chief operating officer on October 5, 2026, with responsibility for manufacturing and execution. Jerh Collins, Moderna's chief technical operations and quality officer, is retiring, according to finanzen.ch.

The management change arrives as Moderna prepares for additional data on intismeran autogene, its personalized cancer vaccine developed with Merck. The company has scheduled a presentation of Phase 3 melanoma data for October 24, 2026, according to Moderna.

Citi raises target but cuts rating

Citi downgraded Moderna from Neutral to Sell on September 30, 2026, while raising its price target from USD 60.00 to USD 80.00. The target increase does not remove the valuation gap: the new target is USD 86.54 below the Lang & Schwarz euro quote on an unconverted currency basis, so the two prices are not directly comparable. The rating and target change were reported by MarketWatch.

Second-quarter loss stays substantial

Moderna reported USD 145.0 million of revenue and a GAAP diluted loss of USD 1.97 per share in the second quarter of 2026. Revenue increased 2.10 percent year over year, while the company posted a GAAP net loss of USD 782.0 million, according to MarketBeat. The figures put the oncology pipeline in a clear financial context: future commercial success must offset a business still operating at a quarterly loss.

Stock remains below its yearly high

Moderna's primary listing is on the NASDAQ, where the stock's 52-week range was USD 22.28 to USD 208.90 as of September 30, 2026. Its market capitalization was USD 76.4 billion on that date, placing the current valuation near the upper end of the annual range while the latest quarterly loss remains substantial.

Intraday quote sets the reference

At Lang & Schwarz, Moderna was trading at EUR 166.54 on October 1, 2026 at 10:03 a.m. CEST, down 1.40 percent versus the prior close of EUR 168.91 on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.